With a former Amgen scientist now at the helm, MannKind is betting that a restructured sales effort, a nearly $50 million war chest and a move to Westlake Village will pay off in new customers and long-elusive profits. In early August, the Valencia-based maker of an inhalable insulin product to treat diabetes will move into…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
